Novel Biologic Agents for Non-HL and CLL — Par... - CLL Support

CLL Support

22,367 members38,474 posts

Novel Biologic Agents for Non-HL and CLL — Part 2: Adoptive Cellular Immunotherapy, Small-Molecule Inhibitors, and Immunomodulation

AussieNeil profile image
AussieNeilAdministrator
0 Replies

Tanya Siddiqi, MD and Steven T. Rosen, MD complete their comprehensive review in part 2:

"In this two-part review, we discuss biologic therapies classified by their targets and mechanisms of action that have received US Food and Drug Administration (FDA) approval for the treatment of non-Hodgkin lymphoma in the last 5 years, as well as promising agents that are more advanced in development. In Part 1, we focused on monoclonal antibodies, while here in Part 2 we primarily review adoptive cellular immunotherapies, small-molecule inhibitors, and immunomodulatory agents. "

* Chimeric antigen receptor (CAR) T cells

* Bruton tyrosine kinase (BTK) inhibitors (Ibrutinib)

* PI3K delta inhibitors (Idelalisib, Duvelisib (IPI-145), TGR-1202, )

* BCL-2 family inhibitors (Navitoclax (ABT-263), ABT-199

* Immunomodulation (Lenalidomide)

* Other Novel Therapies

Small Molecules, Big Challenges

Bruce Cheson, MD, introduces his editorial concerning the above with the words "Recently, my medical students requested a lecture on the topic of “chemotherapy in hematologic malignancies.” I explained that I was unable to comply because the subject was archaic: with each passing year, chemotherapy is less and less a focus of interest. Instead, the focus is on the abundance of exciting new biologic and targeted agents that are bulldozing the therapeutic landscape in the lymphomas and chronic lymphocytic leukemia, with many of these new agents in oral form and most well-tolerated."

cancernetwork.com/oncology-...

Part 1:

healthunlocked.com/cllsuppo...

Neil

Photo: Galah readying for flight. Large flocks of corellas and galahs are building up in eucalyptus trees bordering freshly cultivated paddocks, waiting for cereal grains to sprout so that they can pull up the plant and eat the sprouting grain seed.

Written by
AussieNeil profile image
AussieNeil
Administrator
To view profiles and participate in discussions please or .
Read more about...

You may also like...

Revolution of Chronic Lymphocytic LeukemiaTherapy: the Chemo-Free Treatment Paradigm

Purpose of Review Over the last years, targeted anticancer therapy with small molecule inhibitors...

Novel Bruton’s Tyrosine Kinase (BTK) inhibitor, ONO-4059 enters UK CLL clinical trial

new BTK inhibitor enters the fray in Chronic Lymphocytic Leukaemia and Small Lymphocytic Lymphoma....

A Conversation with Dr Tam about Zanubrutinib: A Novel BTK Inhibitor

ubrutinib-a-novel-btk-inhibitor-in-chronic-lymphocytic-leukemia-and-non-hodgkin-lymphoma/ Jackie

The current status and challenges of CAR-T therapy in CLL

lymphoblastic leukemia (ALL), and non-Hodgkin lymphoma (NHL), there has been less success with...

Sequential And Combination Treatments With Novel Agents (Oct. 2019)

patients with chronic lymphocytic leukemia for a long time. Over the last years, novel agents have...